2Dworkin RH, Portenoy RK. Pain and its persistence in herpes zoster. Pain, 1996, 67 : 241 - 251.
3Dworkin RH, Schmader KE. The epidemiology and natural history of herpes zoster and postherpetic neuralgia. In: Watson CPN, ed. Herpes Zoster and Postherpetic Neuralgia. Amsterdam : Elsevier, 2001, 39 - 65.
4Schmader K, Gnann JW Jr, demiological, clinical, and for the herpes zoster vaccine Watson CP. The epi- pathological rationale J Infect Dis, 2008,197(Suppl 2) :S207 -S215.
5Dworkin RH, Gnann JW Jr, Oaklander AL, et al. Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain,2008, 9(Suppl 1):S37 -S44.
6Johnson RW. Zoster-associated pain:what is known, who is at risk and how can it be managed? Herpes, 2007, 14(Suppl 2) - 30 -34.
7Kost RG, Straus SE. Postherpetic neuralgia - path-ogenesis, treatment, and prevention. N Engl J Med, 1996,335: 32-42.
8Gauthier A, Breuer J, Carrington D, et al. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect, 2009,137 : 38 -47.
9Stein AN, Britt H, Harrison C, et al. Herpes zos- ter burden of illness and health care resource utilisation in the Australian population aged 50 years and older. Vaccine,2009,27 : 520-529.
10Russell ML, Schopflocher DP, Svenson L, et al. Secular trends in the epidemiology of shingles in Al- berta. Epidemiol Infect, 2007,135:908 -913.
